Natixis Advisors LLC Has $50.78 Million Stake in Stryker Co. (NYSE:SYK)

Natixis Advisors LLC boosted its stake in shares of Stryker Co. (NYSE:SYK) by 2.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 149,231 shares of the medical technology company’s stock after buying an additional 3,716 shares during the quarter. Natixis Advisors LLC’s holdings in Stryker were worth $50,776,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Burkett Financial Services LLC bought a new stake in Stryker in the fourth quarter valued at approximately $25,000. Central Pacific Bank Trust Division acquired a new stake in shares of Stryker during the first quarter worth $39,000. DSM Capital Partners LLC bought a new position in Stryker during the fourth quarter worth $34,000. Private Wealth Management Group LLC acquired a new position in Stryker in the fourth quarter valued at $40,000. Finally, Advantage Trust Co bought a new stake in Stryker during the fourth quarter valued at $60,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $360.42 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The firm has a market cap of $137.35 billion, a P/E ratio of 41.14, a PEG ratio of 2.78 and a beta of 0.91. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The firm has a 50-day moving average of $337.13 and a 200 day moving average of $341.52.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period last year, the business posted $2.54 earnings per share. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, research analysts expect that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Monday, September 30th. Stryker’s payout ratio is currently 36.53%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SYK shares. BTIG Research boosted their price objective on Stryker from $360.00 to $374.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Stifel Nicolaus reduced their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $386.00 price objective on shares of Stryker in a research note on Wednesday, July 31st. Needham & Company LLC raised their price target on shares of Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Truist Financial dropped their price objective on shares of Stryker from $364.00 to $345.00 and set a “hold” rating on the stock in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $373.84.

Insider Buying and Selling

In other Stryker news, insider Viju Menon sold 600 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Viju Menon sold 600 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 190,000 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the completion of the sale, the director now directly owns 3,316,608 shares in the company, valued at $1,072,790,023.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 210,600 shares of company stock valued at $68,330,400. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.